Scheme 3 a-Fluoro-b-keto esters in the synthesis of 3-fluorocoumarins, 4-fluoropyrazoles, and 5-fluoropyrimidin-4-ols.
into a single operation obviating the need to isolate the a-fluoro-b-
keto ester. Thus the a-diazo-b-keto ester 1a was treated with
tetrafluoroboric acid etherate in dichloromethane as described
above. After 5 h, ethanol, acetamidine hydrochloride and
DBU were added sequentially to give 5-fluoro-2-methyl-6-
phenylpyrimidin-4-ol 5a in 66% yield. Likewise a-diazo-b-
keto ester 1e was converted into fluoropyrimidinol 5h in
42% yield in a single operation.
10 There are examples of fluorination by halide exchange. However this
requires the starting halo-arene or -hetarene to be (a) sufficiently
activated to SNAr reaction, and (b) readily synthetically accessible.
11 M. P. Doyle, M. A. McKervey and T. Ye, Modern Catalytic
Methods for Organic Synthesis with Diazo Compounds, John Wiley,
New York, 1998.
12 D. J. Miller and C. J. Moody, Tetrahedron, 1995, 51, 10811–10843.
13 H. E. Bartrum, D. C. Blakemore, C. J. Moody and C. J. Hayes,
Chem.–Eur. J., 2011, 17, 9586–9589.
14 M. Hu, C. Ni and J. Hu, J. Am. Chem. Soc., 2012, 134, 15257–15260.
15 J. R. Breen, G. Sandford, D. S. Yufit, J. A. K. Howard, J. Fray
and B. Patel, Beilstein J. Org. Chem., 2011, 7, 1048–1054.
16 T. Kitamura, S. Kuriki, M. H. Morshed and Y. Hori, Org. Lett.,
2011, 13, 2392–2394.
In conclusion, we have developed new methodology, whereby
a-fluoro-b-ketoesters can be easily obtained by nucleophilic
fluorination with tetrafluoroboric acid, by treating readily
available a-diazo-b-ketoesters with HBF4 either using conven-
tional batch chemistry or in flow. The overall process amounts
to a novel variation on the Balz–Schiemann reaction, and the
versatility of the resulting a-fluoro-b-ketoesters is illustrated in the
synthesis of a wide range of fluoro-heterocycles. We believe that
this is an exciting development that will both complement and
challenge existing fluorination methodologies, allowing access to a
wide diversity of fluorinated pharmaceuticals and agrochemicals.
We thank the EPSRC (Grant EP/G027919/1) for support.
17 G. A. Olah, J. T. Welch, Y. D. Vankar, M. Nojima, I. Kerekes and
J. A. Olah, J. Org. Chem., 1979, 44, 3872–3881.
18 J. Hooz and S. Linke, J. Am. Chem. Soc., 1968, 90, 5936–5937.
19 J. Hooz, J. N. Bridson, J. G. Calzada, H. C. Brown, M. M. Midland
and A. B. Levy, J. Org. Chem., 1973, 38, 2574–2576.
20 M. Ohno, M. Itoh, T. Ohashi and S. Eguchi, Synthesis, 1993,
793–796.
21 I. R. Baxendale, S. V. Ley, A. C. Mansfield and C. D. Smith,
Angew. Chem., Int. Ed., 2009, 48, 4017–4021.
22 H. E. Bartrum, D. C. Blakemore, C. J. Moody and C. J. Hayes,
J. Org. Chem., 2010, 75, 8674–8676.
23 L. J. Martin, A. L. Marzinzik, S. V. Ley and I. R. Baxendale,
Org. Lett., 2011, 13, 320–323.
24 C. E. Stephens and J. A. Blake, J. Fluorine Chem., 2004, 125,
1939–1945.
Notes and references
1 K. Muller, C. Faeh and F. Diederich, Science, 2007, 317, 1881–1886.
¨
25 T. F. Campbell and C. E. Stephens, J. Fluorine Chem., 2006, 127,
1591–1594.
26 K. Harada, H. Kubo, Y. Tomigahara, K. Nishioka, J. Takahashi,
M. Momose, S. Inoue and A. Kojima, Bioorg. Med. Chem. Lett.,
2010, 20, 272–275.
27 S. R. F. Kagaruki, T. Kitazume and N. Ishikawa, Bull. Chem.
Soc. Jpn., 1981, 54, 3221–3222.
28 R. Surmont, G. Verniest and N. De Kimpe, Org. Lett., 2010, 12,
4648–4651.
29 J. Qian, Y. Liu, J. Zhu, B. Jiang and Z. Xu, Org. Lett., 2011, 13,
4220–4223.
30 M. D. Hill and M. Movassaghi, Chem.–Eur. J., 2008, 14,
6836–6844.
31 Z. Xu, Z. Liu, T. Chen, T. Chen, Z. Wang, G. Tian, J. Shi,
X. Wang, Y. Lu, X. Yan, G. Wang, H. Jiang, K. Chen, S. Wang,
Y. Xu, J. Shen and W. Zhu, J. Med. Chem., 2011, 54, 5607–5611.
32 D. Alker, S. F. Campbell, P. E. Cross, R. A. Burges, A. J. Carter
and D. G. Gardiner, J. Med. Chem., 1989, 32, 2381–2388.
2 At present ca. 20% of marketed medicines and ca. 30% of
agrochemicals contain at least one fluorine atom (ref. 3). The trend
towards fluorinated bioactives continues: in 2011, three out of the
10 top-selling drugs contained fluorine, as did seven out the 35 newly
approved drugs in that year (ref. 4).
3 S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, Chem. Soc.
Rev., 2008, 37, 320–330.
4 S. K. Ritter, Chem. Eng. News, 2012, 90, 10–17.
5 T. Furuya, A. S. Kamlet and T. Ritter, Nature, 2011, 473, 470–477.
6 S. Yamada, A. Gavryushin and P. Knochel, Angew. Chem., Int.
Ed., 2010, 49, 2215–2218.
7 P. Anbarasan, H. Neumann and M. Beller, Angew. Chem., Int. Ed.,
2010, 49, 2219–2222.
8 P. Tang, W. Wang and T. Ritter, J. Am. Chem. Soc., 2011, 133,
11482–11484.
9 T. J. Maimone, P. J. Milner, T. Kinzel, Y. Zhang, M. K. Takase
and S. L. Buchwald, J. Am. Chem. Soc., 2011, 133, 18106–18109.
c
This journal is The Royal Society of Chemistry 2012
Chem. Commun., 2012, 48, 12077–12079 12079